Genetics

Global DNA Sequencing Technologies, Markets and Companies Report 2018 Featuring Profiles of 145 Companies with Theor 161 Collaborations

Retrieved on: 
Tuesday, July 24, 2018
Biology, Molecular biology, Genetics, Biotechnology, DNA, Genomics, DNA sequencing, Sequencing, Whole genome sequencing, Molecular diagnostics

The "DNA Sequencing - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "DNA Sequencing - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
  • This report briefly reviews basics of human genome variations, development of sequencing technologies, and their applications.
  • Various applications of sequencing are described including those for genetics, medical diagnostics, drug discovery and cancer.
  • The report includes profiles of 145 companies involved in sequencing and their 161 collaborations.

Enterprise Adoption of RPA Exceeds 100% Growth in 2017, Buoyed by New Buyers of All Sizes, Industries--Everest Group

Retrieved on: 
Monday, July 23, 2018
Genetics, Replication protein A, RPA, Adoption

Enterprises of all sizes and industries are testing the RPA waters, eager to keep pace with their peers in the technology adoption curve.

Key Points: 
  • Enterprises of all sizes and industries are testing the RPA waters, eager to keep pace with their peers in the technology adoption curve.
  • Enterprise adoption of RPA, as indicated by the number of enterprise clients served by independent RPA vendors, achieved a 105 percent growth rate from 2016 to 2017, according to Everest Group.
  • The market is in its early stages of high growth and adoption, with most enterprises testing the water at this stage."
  • The majority of RPA buyers are still in an early adoption phase, as they continue to test the technology before scaling up.

Global Biochips and Microarrays Companies, Technologies and Markets 2017-2027 - 91 Companies are Included Along with Listing of 119 Collaborations

Retrieved on: 
Wednesday, July 18, 2018
Biology, Genetics, Molecular biology, Microarrays, Bioinformatics, Genomics, DNA, Comparative genomic hybridization, Biochip, DNA methylation, Copy-number variation, ChIP-on-chip

The "Biochips and Microarrays - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biochips and Microarrays - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
  • The report starts with a description of technologies as a basis for estimation of markets.
  • Technologies include array comparative genomic hybridization (CGH), copy number variation (CNV), DNA methylation, ChIP-Chip, RNA splice variants, and microRNA.
  • Currently selected 91 companies are included along with listing of 119 collaborations between companies.

Gene Therapies: A Growing Pipeline and Approval of CAR-T Cell Therapies Reflect Increasing Commercial Appeal, Despite Difficulties Faced by products such as Glybera and Strimvelis

Retrieved on: 
Wednesday, July 18, 2018
Biology, Genetics, Molecular biology, RNA, Gene expression, Applied genetics, Gene delivery, Cancer treatments, Chimeric antigen receptor, Alipogene tiparvovec, RNA interference

NEW YORK, July 18, 2018 /PRNewswire/ -- Gene Therapies: A Growing Pipeline and Approval of CAR-T Cell Therapies Reflect Increasing Commercial Appeal, Despite Difficulties Faced by products such as Glybera and Strimvelis

Key Points: 
  • NEW YORK, July 18, 2018 /PRNewswire/ -- Gene Therapies: A Growing Pipeline and Approval of CAR-T Cell Therapies Reflect Increasing Commercial Appeal, Despite Difficulties Faced by products such as Glybera and Strimvelis
    GBI Research's latest report: "Gene Therapies: A Growing Pipeline and Approval of CAR-T Cell Therapies Reflect Increasing Commercial Appeal, Despite Difficulties Faced by products such as Glybera and Strimvelis" discusses all gene therapies, including not only those which involve genetic modification, but also RNAi, CAR-T cell and aptamer-based therapies.
  • However, the pipeline for gene therapies is robust; there are 985 in vivo gene therapies, and a further 354 CAR-T cell therapies currently in pipeline development.
  • - What can be learned from the gene therapies that have already reached the market, especially from products that have faced commercial difficulties, such as Glybera and Strimvelis?
  • - Understand the current status of the field of therapeutic gene therapies, and the relative clinical and commercial success of currently marketed products.

Kalorama Information: Beyond 23andMe.com, A Direct-to-Consumer Genetic Testing Industry Emerges

Retrieved on: 
Wednesday, July 18, 2018
Genetics, Medicine, Health, Applied genetics, Alternatives to animal testing, Genetic testing, 23andMe, Direct-to-consumer advertising, Predisposition

ROCKVILLE, Md., July 18, 2018 /PRNewswire/ -- Healthcare market research firm Kalorama Information says that the global direct-to-consumer (DTC) genetic health testing market totaled $99 million in 2017.

Key Points: 
  • ROCKVILLE, Md., July 18, 2018 /PRNewswire/ -- Healthcare market research firm Kalorama Information says that the global direct-to-consumer (DTC) genetic health testing market totaled $99 million in 2017.
  • Strong growth is expected through the forecast period due to easing of the regulatory process for DTC genetic tests.
  • While 23andMe.com leads the market, Kalorama Information says part of that future growth is expected to come from new competitors, including:
    EasyDNA in Elk Grove, CA offers DNA testing for celiac disease and genetic testing for cancer and predisposition and genetic disease predisposition.
  • Kalorama Information's report, The Market for Direct-to-Consumer Genetic Testing, is available at https://www.kaloramainformation.com/Direct-Consumer-Genetic-Health-Testi... .

Global RNAi Technologies, Markets and Companies 2017-2027

Retrieved on: 
Tuesday, July 17, 2018
Biology, Genetics, RNA, Health, Gene expression, RNA interference, RNAI, Clinical trial

The "RNAi - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "RNAi - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
  • The markets for RNAi are difficult to define as no RNAi-based product is approved yet but several are in clinical trials.
  • Profiles of 164 companies involved in developing RNAi technologies are presented along with 232 collaborations.
  • They are a mix of companies that supply reagents and technologies (nearly half of all) and companies that use the technologies for drug discovery.

Cryoport Partners with World Courier to Provide Best-In-Class Logistics Platform for Global Cell and Gene Therapy Market

Retrieved on: 
Monday, July 16, 2018
Biology, Genetics, Logistics, Systems engineering, Courier, Gene therapy

This agreement between World Courier and Cryoport is for an initial three-year period with an evergreen provision.

Key Points: 
  • This agreement between World Courier and Cryoport is for an initial three-year period with an evergreen provision.
  • We are proud that it will be integrated into World Courier's current offerings and to provide a seamless platform within the precision medicine space.
  • This collaboration offers a more diverse range of reliable temperature-controlled solutions to our cell and gene therapy clients around the world."
  • World Courier is a global specialty logistics company that designs world-class supply chain programs in complete alignment with customers' business goals.

Exclusive Orig3n Mind & Body DNA Test Offered on Amazon Prime Day

Retrieved on: 
Monday, July 16, 2018
Biology, Biological specimens, Biotechnology, Molecular biology, DNA, Genetics, Helices, Sampling, Buccal swab, Genetic testing, Amazon Prime

Orig3n, a Boston-based biotech company pioneering the future of medicine through genetics and regenerative medicine, today announced an exclusive product designed specifically for Prime Day to deliver superior value for Amazon Prime Members.

Key Points: 
  • Orig3n, a Boston-based biotech company pioneering the future of medicine through genetics and regenerative medicine, today announced an exclusive product designed specifically for Prime Day to deliver superior value for Amazon Prime Members.
  • Available for the special price of $49, Orig3n's Mind & Body DNA test delivers unique insights into the important role genes play in how the mind and body work.
  • "We are excited to bring this exclusive new Mind & Body DNA test to Amazon Prime members," said Robin Y. Smith, CEO of Orig3n.
  • The Mind & Body DNA Test Kit includes easy-to-follow instructions, a cheek swab for no-mess sample collection, and a prepaid return envelope.

Inscripta Granted Patents for CRISPR Gene-Editing Systems

Retrieved on: 
Thursday, July 12, 2018
Biology, Genetics, Biotechnology, Immune system, Biological engineering, Emerging technologies, Molecular biology, CRISPR, Mad2, United States Patent and Trademark Office, Patent

First, the USPTO granted Inscripta its first patent covering systems using MAD7, the company's first free CRISPR enzyme, as well as patent coverage for systems using another MADzyme, MAD2.

Key Points: 
  • First, the USPTO granted Inscripta its first patent covering systems using MAD7, the company's first free CRISPR enzyme, as well as patent coverage for systems using another MADzyme, MAD2.
  • "Today marks a major step forward in the gene-editing revolution we started seven months ago when we released our own, unique CRISPR enzyme (MAD7)," said Kevin Ness, CEO of Inscripta.
  • The patents confirm the novelty of using MAD7 and MAD2 enzymes in editing systems in multiple cell types, including microbes, plants, and mammalian systems.
  • The applicable terms and conditions include a license to Inscripta's patents covering systems using MAD7.

2018 Global Strategic Business Report: Direct-to-Consumer (DTC) Genetic Testing - High Potential Benefits, But Concerns Persist

Retrieved on: 
Thursday, July 12, 2018
Genetics, Biology, Breast cancer, Medicine, Tumor markers, Tumor suppressor genes, Medical genetics, Applied genetics, 23andMe, BRCA2, Genetic testing, BRCA

Quest Diagnostics and Inserm Launch BRCA Share, a Datashare Initiative with Open Access to BRCA1 and BRCA2 Genetic Data

Key Points: 

Quest Diagnostics and Inserm Launch BRCA Share, a Datashare Initiative with Open Access to BRCA1 and BRCA2 Genetic Data
23andMe Bags FDA Approval for Personal Genome Service, a DTC Genetic Test for Bloom Syndrome